© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 16, 1295-1302,
August 16, 2000
© 2000 Oxford University Press
REVIEW |
A Family of Drug Transporters: the Multidrug Resistance-Associated Proteins
Affiliation of authors: Division of Molecular Biology and Center of Biomedical Genetics, The Netherlands Cancer Institute, Amsterdam.
Correspondence to: Piet Borst, M.D., Ph.D., Division of Molecular Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands (e-mail: pborst{at}nki.nl).
The human multidrug resistance-associated protein (MRP) family currently has seven members. The ability of several of these membrane proteins to transport a wide range of anticancer drugs out of cells and their presence in many tumors make them prime suspects in unexplained cases of drug resistance, although proof that they contribute to clinical drug resistance is still lacking. Recent studies have begun to clarify the function of the MRP family members. MRPs are organic anion transporters; i.e., they transport anionic drugs, exemplified by methotrexate, and neutral drugs conjugated to acidic ligands, such as glutathione (GSH), glucuronate, or sulfate. However, MRP1, MRP2, and MRP3 can also cause resistance to neutral organic drugs that are not known to be conjugated to acidic ligands by transporting these drugs together with free GSH. MRP1 can even confer resistance to arsenite and MRP2 to cisplatin, again probably by transporting these compounds in complexes with GSH. MRP4 overexpression is associated with high-level resistance to the nucleoside analogues 9-(2-phosphonylmethoxyethyl) adenine and azidothymidine, both of which are used as anti-human immunodeficiency virus drugs. MRPs may, therefore, also have a role in resistance against nucleoside analogues used in cancer chemotherapy. Mice without Mrp1, a high-affinity leukotriene C4 transporter, have an altered response to inflammatory stimuli but are otherwise healthy and fertile. MRP2 is the major transporter responsible for the secretion of bilirubin glucuronides into bile, and humans without MRP2 develop a mild liver disease known as the Dubin–Johnson syndrome. The physiologic functions of the other MRPs are not known. Whether long-term inhibition of MRPs in humans can be tolerated (assuming that suitable inhibitors will be found) remains to be determined.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Aiba, A. Hossain, and M. T. Kuo Elevated GSH Level Increases Cadmium Resistance through Down-Regulation of Sp1-Dependent Expression of the Cadmium Transporter ZIP8 Mol. Pharmacol., September 1, 2008; 74(3): 823 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Johnatty, J. Beesley, J. Paul, S. Fereday, A. B. Spurdle, P. M. Webb, K. Byth, S. Marsh, H. McLeod, AOCS Study Group, et al. ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy Clin. Cancer Res., September 1, 2008; 14(17): 5594 - 5601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Yoshida, T. Takada, Y. Yamamura, I. Adachi, H. Suzuki, and J. Kawakami Inhibitory Effects of Terpenoids on Multidrug Resistance-Associated Protein 2- and Breast Cancer Resistance Protein-Mediated Transport Drug Metab. Dispos., July 1, 2008; 36(7): 1206 - 1211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. O'Brien, G. Cavet, A. Pandita, X. Hu, L. Haydu, S. Mohan, K. Toy, C. S. Rivers, Z. Modrusan, L. C. Amler, et al. Functional Genomics Identifies ABCC3 as a Mediator of Taxane Resistance in HER2-Amplified Breast Cancer Cancer Res., July 1, 2008; 68(13): 5380 - 5389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H.E. Baker, K. E. Lindquist, L. A. Huxham, A. H. Kyle, J. T. Sy, and A. I. Minchinton Direct Visualization of Heterogeneous Extravascular Distribution of Trastuzumab in Human Epidermal Growth Factor Receptor Type 2 Overexpressing Xenografts Clin. Cancer Res., April 1, 2008; 14(7): 2171 - 2179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Lickteig, C. D. Fisher, L. M. Augustine, L. M. Aleksunes, D. G. Besselsen, A. L. Slitt, J. E. Manautou, and N. J. Cherrington Efflux Transporter Expression and Acetaminophen Metabolite Excretion Are Altered in Rodent Models of Nonalcoholic Fatty Liver Disease Drug Metab. Dispos., October 1, 2007; 35(10): 1970 - 1978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lonning, S Knappskog, V Staalesen, R Chrisanthar, and J. Lillehaug Breast cancer prognostication and prediction in the postgenomic era Ann. Onc., August 1, 2007; 18(8): 1293 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Madejczyk, D. A. Aremu, T. A. Simmons-Willis, T. W. Clarkson, and N. Ballatori Accelerated Urinary Excretion of Methylmercury following Administration of Its Antidote N-Acetylcysteine Requires Mrp2/Abcc2, the Apical Multidrug Resistance-Associated Protein J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 378 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Luo, C. E. Garner, H. Xiong, H. Hu, L. E. Richards, K. L. R. Brouwer, J. Duan, C. P. Decicco, T. Maduskuie, H. Shen, et al. Effect of DPC 333 [(2R)-2-{(3R)-3-Amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a Human Tumor Necrosis Factor {alpha}-Converting Enzyme Inhibitor, on the Disposition of Methotrexate: A Transporter-Based Drug-Drug Interaction Case Study Drug Metab. Dispos., June 1, 2007; 35(6): 835 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Lai, L. Xing, G. I. Poda, and Y. Hu Structure-Activity Relationships for Interaction with Multidrug Resistance Protein 2 (ABCC2/MRP2): The Role of Torsion Angle for a Series of Biphenyl-Substituted Heterocycles Drug Metab. Dispos., June 1, 2007; 35(6): 937 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Han, L. Li, S. Qiu, Q. Lu, Q. Pan, Y. Gu, J. Luo, and X. Hu Shikonin circumvents cancer drug resistance by induction of a necroptotic death Mol. Cancer Ther., May 1, 2007; 6(5): 1641 - 1649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Neuzil, M. Tomasetti, Y. Zhao, L.-F. Dong, M. Birringer, X.-F. Wang, P. Low, K. Wu, B. A. Salvatore, and S. J. Ralph Vitamin E Analogs, a Novel Group of "Mitocans," as Anticancer Agents: The Importance of Being Redox-Silent Mol. Pharmacol., May 1, 2007; 71(5): 1185 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Deeken and W. Loscher The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses Clin. Cancer Res., March 15, 2007; 13(6): 1663 - 1674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Weiss, D. Theile, N. Ketabi-Kiyanvash, H. Lindenmaier, and W. E. Haefeli Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by Nucleoside, Nucleotide, and Non-Nucleoside Reverse Transcriptase Inhibitors Drug Metab. Dispos., March 1, 2007; 35(3): 340 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Seo, E. Hatano, T. Higashi, T. Hara, M. Tada, N. Tamaki, K. Iwaisako, I. Ikai, and S. Uemoto Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Predicts Tumor Differentiation, P-glycoprotein Expression, and Outcome after Resection in Hepatocellular Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 427 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Baltes, M. Fedrowitz, C. L. Tortos, H. Potschka, and W. Loscher Valproic Acid Is Not a Substrate for P-glycoprotein or Multidrug Resistance Proteins 1 and 2 in a Number of in Vitro and in Vivo Transport Assays J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 331 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Wever, R. Masereeuw, D. S. Miller, X. M. Hang, and G. Flik Endothelin and calciotropic hormones share regulatory pathways in multidrug resistance protein 2-mediated transport Am J Physiol Renal Physiol, January 1, 2007; 292(1): F38 - F46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. W. Velsor, C. Kariya, R. Kachadourian, and B. J. Day Mitochondrial Oxidative Stress in the Lungs of Cystic Fibrosis Transmembrane Conductance Regulator Protein Mutant Mice Am. J. Respir. Cell Mol. Biol., November 1, 2006; 35(5): 579 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Meletiadis, S. Chanock, and T. J. Walsh Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy Clin. Microbiol. Rev., October 1, 2006; 19(4): 763 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Michael, M. Thompson, R. J. Hicks, P. L. Mitchell, A. Ellis, A. D. Milner, J. Di Iulio, A. M. Scott, V. Gurtler, J. M. Hoskins, et al. Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination J. Clin. Oncol., September 10, 2006; 24(26): 4228 - 4235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Deeley, C. Westlake, and S. P. C. Cole Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins. Physiol Rev, July 1, 2006; 86(3): 849 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dallas, D. S. Miller, and R. Bendayan Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol. Rev., June 1, 2006; 58(2): 140 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. van de Ven, M. C. de Jong, A. W. Reurs, A. J. N. Schoonderwoerd, G. Jansen, J. H. Hooijberg, G. L. Scheffer, T. D. de Gruijl, and R. J. Scheper Dendritic Cells Require Multidrug Resistance Protein 1 (ABCC1) Transporter Activity for Differentiation J. Immunol., May 1, 2006; 176(9): 5191 - 5198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Haber, J. Smith, S. B. Bordow, C. Flemming, S. L. Cohn, W. B. London, G. M. Marshall, and M. D. Norris Association of High-Level MRP1 Expression With Poor Clinical Outcome in a Large Prospective Study of Primary Neuroblastoma J. Clin. Oncol., April 1, 2006; 24(10): 1546 - 1553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Kis, T. Isse, J. A. Snipes, L. Chen, H. Yamashita, Y. Ueta, and D. W. Busija Effects of LPS stimulation on the expression of prostaglandin carriers in the cells of the blood-brain and blood-cerebrospinal fluid barriers J Appl Physiol, April 1, 2006; 100(4): 1392 - 1399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Morrow, C. Peklak-Scott, B. Bishwokarma, T. E. Kute, P. K. Smitherman, and A. J. Townsend Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediates Resistance to Mitoxantrone via Glutathione-Dependent Drug Efflux Mol. Pharmacol., April 1, 2006; 69(4): 1499 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhang, M. A. Alston, H. Huang, and R. L. Rabin Human T cell cytokine responses are dependent on multidrug resistance protein-1 Int. Immunol., March 1, 2006; 18(3): 485 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Remy and H. Beck Molecular and cellular mechanisms of pharmacoresistance in epilepsy Brain, January 1, 2006; 129(1): 18 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L.A. Plasschaert, E. S.J.M. de Bont, M. Boezen, D. M. vander Kolk, S. M.J.G. Daenen, K. N. Faber, W. A. Kamps, E. G.E. de Vries, and E. Vellenga Expression of Multidrug Resistance-Associated Proteins Predicts Prognosis in Childhood and Adult Acute Lymphoblastic Leukemia Clin. Cancer Res., December 15, 2005; 11(24): 8661 - 8668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ballatori Biology of a Novel Organic Solute and Steroid Transporter, OST{alpha}-OST{beta} Experimental Biology and Medicine, November 1, 2005; 230(10): 689 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-K. Kang, E. Lee, H. Pyo, and S.-J. Lim Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells Mol. Cancer Ther., September 1, 2005; 4(9): 1358 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-f. Zhou, X. Yang, Q. Wang, R. A. Coburn, and M. E. Morris EFFECTS OF DIHYDROPYRIDINES AND PYRIDINES ON MULTIDRUG RESISTANCE MEDIATED BY BREAST CANCER RESISTANCE PROTEIN: IN VITRO AND IN VIVO STUDIES Drug Metab. Dispos., August 1, 2005; 33(8): 1220 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. E. Meyer zu Schwabedissen, G. Jedlitschky, M. Gratz, S. Haenisch, K. Linnemann, C. Fusch, I. Cascorbi, and H. K. Kroemer VARIABLE EXPRESSION OF MRP2 (ABCC2) IN HUMAN PLACENTA: INFLUENCE OF GESTATIONAL AGE AND CELLULAR DIFFERENTIATION Drug Metab. Dispos., July 1, 2005; 33(7): 896 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Wielinga, J. H. Hooijberg, S. Gunnarsdottir, I. Kathmann, G. Reid, N. Zelcer, K. van der Born, M. de Haas, I. van der Heijden, G. Kaspers, et al. The Human Multidrug Resistance Protein MRP5 Transports Folates and Can Mediate Cellular Resistance against Antifolates Cancer Res., May 15, 2005; 65(10): 4425 - 4430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Burckhardt Polyspecific Organic Cation Transport: Insights into the Substrate Binding Site Mol. Pharmacol., May 1, 2005; 67(5): 1391 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zhang, X. Tian, P. Chandra, and K. L. R. Brouwer Role of Glycosylation in Trafficking of Mrp2 in Sandwich-Cultured Rat Hepatocytes Mol. Pharmacol., April 1, 2005; 67(4): 1334 - 1341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Wolf, T Stranzl, M Filipits, G Pohl, R Pirker, B Leeb, and J S Smolen Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis Ann Rheum Dis, April 1, 2005; 64(4): 564 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Park and P. J. Sinko P-Glycoprotein and Mutlidrug Resistance-Associated Proteins Limit the Brain Uptake of Saquinavir in Mice J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1249 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Benlloch, A. Ortega, P. Ferrer, R. Segarra, E. Obrador, M. Asensi, J. Carretero, and J. M. Estrela Acceleration of Glutathione Efflux and Inhibition of {gamma}-Glutamyltranspeptidase Sensitize Metastatic B16 Melanoma Cells to Endothelium-induced Cytotoxicity J. Biol. Chem., February 25, 2005; 280(8): 6950 - 6959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Filipits, G. Pohl, M. Rudas, O. Dietze, S. Lax, R. Grill, R. Pirker, C. C. Zielinski, H. Hausmaninger, E. Kubista, et al. Clinical Role of Multidrug Resistance Protein 1 Expression in Chemotherapy Resistance in Early-Stage Breast Cancer: The Austrian Breast and Colorectal Cancer Study Group J. Clin. Oncol., February 20, 2005; 23(6): 1161 - 1168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Sharma, J. L. Prior, M. G. Belinsky, G. D. Kruh, and D. Piwnica-Worms Characterization of a 67Ga/68Ga Radiopharmaceutical for SPECT and PET of MDR1 P-Glycoprotein Transport Activity In Vivo: Validation in Multidrug-Resistant Tumors and at the Blood-Brain Barrier J. Nucl. Med., February 1, 2005; 46(2): 354 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. M. H. Van Aubel, P. H. E. Smeets, J. J. M. W. van den Heuvel, and F. G. M. Russel Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites Am J Physiol Renal Physiol, February 1, 2005; 288(2): F327 - F333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Michael and M.M. Doherty Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy J. Clin. Oncol., January 1, 2005; 23(1): 205 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Aleksunes, A. M. Slitt, N. J. Cherrington, M. S. Thibodeau, C. D. Klaassen, and J. E. Manautou Differential Expression of Mouse Hepatic Transporter Genes in Response to Acetaminophen and Carbon Tetrachloride Toxicol. Sci., January 1, 2005; 83(1): 44 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ford, S. H. Khoo, and D. J. Back The intracellular pharmacology of antiretroviral protease inhibitors J. Antimicrob. Chemother., December 1, 2004; 54(6): 982 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Toffoli, G. Corona, G. Cattarossi, M. Boiocchi, G. Di Gennaro, U. Tirelli, and E. Vaccher Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma Ann. Onc., December 1, 2004; 15(12): 1805 - 1809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Cui, Y. Kobayashi, T. Hayakawa, and S. Hirano Arsenic Speciation in Bile and Urine Following Oral and Intravenous Exposure to Inorganic and Organic Arsenics in Rats Toxicol. Sci., December 1, 2004; 82(2): 478 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. St-Pierre, T. Stallmach, A. Freimoser Grundschober, J.-F. Dufour, M. A. Serrano, J. J. G. Marin, Y. Sugiyama, and P. J. Meier Temporal expression profiles of organic anion transport proteins in placenta and fetal liver of the rat Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2004; 287(6): R1505 - R1516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Jedlitschky, K. Tirschmann, L. E. Lubenow, H. K. Nieuwenhuis, J. W. N. Akkerman, A. Greinacher, and H. K. Kroemer The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage Blood, December 1, 2004; 104(12): 3603 - 3610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. E. Sauna, K. Nandigama, and S. V. Ambudkar Multidrug Resistance Protein 4 (ABCC4)-mediated ATP Hydrolysis: EFFECT OF TRANSPORT SUBSTRATES AND CHARACTERIZATION OF THE POST-HYDROLYSIS TRANSITION STATE J. Biol. Chem., November 19, 2004; 279(47): 48855 - 48864. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, J. D. Schuetz, W. F. Elmquist, and D. W. Miller Plasma Membrane Localization of Multidrug Resistance-Associated Protein Homologs in Brain Capillary Endothelial Cells J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 449 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Situ, A. Haimeur, G. Conseil, K. E. Sparks, D. Zhang, R. G. Deeley, and S. P. C. Cole Mutational Analysis of Ionizable Residues Proximal to the Cytoplasmic Interface of Membrane Spanning Domain 3 of the Multidrug Resistance Protein, MRP1 (ABCC1): GLUTAMATE 1204 IS IMPORTANT FOR BOTH THE EXPRESSION AND CATALYTIC ACTIVITY OF THE TRANSPORTER J. Biol. Chem., September 10, 2004; 279(37): 38871 - 38880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Iohom, D. Fitzgerald, and A. J. Cunningham Principles of pharmacogenetics--implications for the anaesthetist Br. J. Anaesth., September 1, 2004; 93(3): 440 - 450. [Full Text] [PDF]
|
|
|
|
|
|
N. Morioka, K. Kumagai, K. Morita, S. Kitayama, and T. Dohi Nonsteroidal Anti-Inflammatory Drugs Potentiate 1-Methyl-4-phenylpyridinium (MPP+)-Induced Cell Death by Promoting the Intracellular Accumulation of MPP+ in PC12 Cells J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 800 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Michot, F. Van Bambeke, M.-P. Mingeot-Leclercq, and P. M. Tulkens Active Efflux of Ciprofloxacin from J774 Macrophages through an MRP-Like Transporter Antimicrob. Agents Chemother., July 1, 2004; 48(7): 2673 - 2682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ito, T. Koresawa, K. Nakano, and T. Horie Mrp2 is involved in benzylpenicillin-induced choleresis Am J Physiol Gastrointest Liver Physiol, July 1, 2004; 287(1): G42 - G49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Wright and W. H. Dantzler Molecular and Cellular Physiology of Renal Organic Cation and Anion Transport Physiol Rev, July 1, 2004; 84(3): 987 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|